Format
Items per page
Sort by

Send to:

Choose Destination

Results: 10

Cited In for PubMed (Select 21150554)

1.

Infection with host-range mutant adenovirus 5 suppresses innate immunity and induces systemic CD4+ T cell activation in rhesus macaques.

Qureshi H, Genescà M, Fritts L, McChesney MB, Robert-Guroff M, Miller CJ.

PLoS One. 2014 Sep 9;9(9):e106004. doi: 10.1371/journal.pone.0106004. eCollection 2014.

2.

Lessons learned from HIV vaccine clinical efficacy trials.

Day TA, Kublin JG.

Curr HIV Res. 2013 Sep;11(6):441-9. Review.

3.

A Recombinant Adenovirus Encoding Multiple HIV-1 Epitopes Induces Stronger CD4+ T cell Responses than a DNA Vaccine in Mice.

Rosa DS, Ribeiro SP, Almeida RR, Mairena EC, Kalil J, Cunha-Neto E.

J Vaccines Vaccin. 2011 Dec 2;2(4). pii: 1000124.

4.

Broadly protective adenovirus-based multivalent vaccines against highly pathogenic avian influenza viruses for pandemic preparedness.

Vemula SV, Ahi YS, Swaim AM, Katz JM, Donis R, Sambhara S, Mittal SK.

PLoS One. 2013 Apr 30;8(4):e62496. doi: 10.1371/journal.pone.0062496. Print 2013.

5.

HIV-1 Vaccine Trials: Evolving Concepts and Designs.

Sanou MP, De Groot AS, Murphey-Corb M, Levy JA, Yamamoto JK.

Open AIDS J. 2012;6:274-88. doi: 10.2174/1874613601206010274. Epub 2012 Nov 30.

6.

Merck Ad5/HIV induces broad innate immune activation that predicts CD8⁺ T-cell responses but is attenuated by preexisting Ad5 immunity.

Zak DE, Andersen-Nissen E, Peterson ER, Sato A, Hamilton MK, Borgerding J, Krishnamurty AT, Chang JT, Adams DJ, Hensley TR, Salter AI, Morgan CA, Duerr AC, De Rosa SC, Aderem A, McElrath MJ.

Proc Natl Acad Sci U S A. 2012 Dec 11;109(50):E3503-12. doi: 10.1073/pnas.1208972109. Epub 2012 Nov 14.

7.

Decreased pre-existing Ad5 capsid and Ad35 neutralizing antibodies increase HIV-1 infection risk in the Step trial independent of vaccination.

Cheng C, Wang L, Gall JG, Nason M, Schwartz RM, McElrath MJ, DeRosa SC, Hural J, Corey L, Buchbinder SP, Nabel GJ.

PLoS One. 2012;7(4):e33969. doi: 10.1371/journal.pone.0033969. Epub 2012 Apr 4. Erratum in: PLoS One. 2012;7(5): doi/10.1371/annotation/805c32e9-70cf-4937-af15-e26de6a11e99. Wang, LingShu [corrected to Wang, Lingshu]..

8.

Preexisting adenovirus seropositivity is not associated with increased HIV-1 acquisition in three HIV-1 vaccine efficacy trials.

Stephenson KE, Hural J, Buchbinder SP, Sinangil F, Barouch DH.

J Infect Dis. 2012 Jun 15;205(12):1806-10. doi: 10.1093/infdis/jis285. Epub 2012 Apr 5.

9.

Low-dose penile SIVmac251 exposure of rhesus macaques infected with adenovirus type 5 (Ad5) and then immunized with a replication-defective Ad5-based SIV gag/pol/nef vaccine recapitulates the results of the phase IIb step trial of a similar HIV-1 vaccine.

Qureshi H, Ma ZM, Huang Y, Hodge G, Thomas MA, DiPasquale J, DeSilva V, Fritts L, Bett AJ, Casimiro DR, Shiver JW, Robert-Guroff M, Robertson MN, McChesney MB, Gilbert PB, Miller CJ.

J Virol. 2012 Feb;86(4):2239-50. doi: 10.1128/JVI.06175-11. Epub 2011 Dec 7.

10.

Advances and future challenges in adenoviral vector pharmacology and targeting.

Khare R, Chen CY, Weaver EA, Barry MA.

Curr Gene Ther. 2011 Aug;11(4):241-58. Review.

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk